Beta Drugs Limited (NSE:BETA)
1,677.00
-53.00 (-3.06%)
At close: Jul 16, 2025
Beta Drugs Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Cash & Equivalents | 1,470 | 286.33 | 191.64 | 173.24 | 104.25 | Upgrade |
Cash & Short-Term Investments | 1,470 | 286.33 | 191.64 | 173.24 | 104.25 | Upgrade |
Cash Growth | 413.49% | 49.41% | 10.62% | 66.18% | 93.52% | Upgrade |
Accounts Receivable | 1,026 | 792.4 | 627.23 | 451.82 | 338.76 | Upgrade |
Other Receivables | - | 125.07 | 81.81 | 71.75 | 38.38 | Upgrade |
Receivables | 1,026 | 917.47 | 709.03 | 523.57 | 377.15 | Upgrade |
Inventory | 597.73 | 498.12 | 306.19 | 224.82 | 160.43 | Upgrade |
Prepaid Expenses | - | 5.24 | 3.27 | 3.13 | 2.87 | Upgrade |
Other Current Assets | 217.02 | 71.52 | 66.71 | 44.84 | 35.72 | Upgrade |
Total Current Assets | 3,311 | 1,779 | 1,277 | 969.59 | 680.41 | Upgrade |
Property, Plant & Equipment | 803.62 | 592.03 | 580.95 | 506.68 | 392.65 | Upgrade |
Long-Term Investments | - | - | 7.79 | 7.79 | 7.79 | Upgrade |
Goodwill | - | 27.46 | 27.46 | 27.46 | 27.46 | Upgrade |
Other Intangible Assets | 85.73 | 26.42 | 19.16 | 15.41 | 7.71 | Upgrade |
Long-Term Deferred Tax Assets | 18.29 | 14.11 | 12.01 | 6.8 | 6.48 | Upgrade |
Other Long-Term Assets | 143.94 | 102.29 | 60 | 44.8 | 52.56 | Upgrade |
Total Assets | 4,362 | 2,541 | 1,984 | 1,579 | 1,175 | Upgrade |
Accounts Payable | 712.77 | 592.73 | 402.4 | 319.52 | 204.94 | Upgrade |
Accrued Expenses | - | 65.11 | 45 | 35.75 | 24.12 | Upgrade |
Short-Term Debt | 57.13 | 49.57 | 90.69 | 47.54 | 35.41 | Upgrade |
Current Portion of Long-Term Debt | - | 37.13 | 42.9 | 40.22 | 27.94 | Upgrade |
Current Income Taxes Payable | 43.12 | 27.97 | 41.7 | 36.31 | 14.19 | Upgrade |
Other Current Liabilities | 214.56 | 74.18 | 7.47 | 10.36 | 26.4 | Upgrade |
Total Current Liabilities | 1,028 | 846.69 | 630.16 | 489.7 | 332.99 | Upgrade |
Long-Term Debt | 1,270 | 60.41 | 69.74 | 118.26 | 111.3 | Upgrade |
Other Long-Term Liabilities | 68.29 | 40.93 | 37.19 | 32.4 | 33.28 | Upgrade |
Total Liabilities | 2,391 | 969.82 | 755.37 | 655.1 | 488.93 | Upgrade |
Common Stock | 100.95 | 96.14 | 96.14 | 96.14 | 96.14 | Upgrade |
Additional Paid-In Capital | - | 239.4 | 239.4 | 239.4 | 239.4 | Upgrade |
Retained Earnings | - | 1,236 | 893.3 | 587.89 | 350.59 | Upgrade |
Comprehensive Income & Other | 1,870 | - | - | - | - | Upgrade |
Shareholders' Equity | 1,971 | 1,571 | 1,229 | 923.43 | 686.13 | Upgrade |
Total Liabilities & Equity | 4,362 | 2,541 | 1,984 | 1,579 | 1,175 | Upgrade |
Total Debt | 1,327 | 147.11 | 203.32 | 206.03 | 174.64 | Upgrade |
Net Cash (Debt) | 143.16 | 139.22 | -11.68 | -32.79 | -70.39 | Upgrade |
Net Cash Growth | 2.84% | - | - | - | - | Upgrade |
Net Cash Per Share | 14.18 | 13.79 | -1.16 | -3.25 | -6.97 | Upgrade |
Filing Date Shares Outstanding | 10.1 | 10.09 | 10.09 | 10.09 | 10.09 | Upgrade |
Total Common Shares Outstanding | 10.1 | 10.09 | 10.09 | 10.09 | 10.09 | Upgrade |
Working Capital | 2,283 | 931.99 | 646.69 | 479.89 | 347.43 | Upgrade |
Book Value Per Share | 195.22 | 155.65 | 121.73 | 91.48 | 67.97 | Upgrade |
Tangible Book Value | 1,885 | 1,517 | 1,182 | 880.55 | 650.96 | Upgrade |
Tangible Book Value Per Share | 186.73 | 150.31 | 117.12 | 87.23 | 64.49 | Upgrade |
Land | - | 19.49 | 19.49 | 19.49 | 19.49 | Upgrade |
Buildings | - | 314.39 | 280.94 | 244.2 | 172.15 | Upgrade |
Machinery | - | 691.13 | 637.66 | 510.62 | 382.7 | Upgrade |
Construction In Progress | - | - | - | - | 28.1 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.